The importance of early immunotherapy in patients with faciobrachial dystonic seizures
Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, Farooque P, Gelfand JM, Geschwind MD, Hirsch LJ, Somerville E, Lang B, Vincent A, Leite MI, Waters P, Irani SR, Dogan-Onugoren M, Rae-Grant A, Illes Z, Szots M, Malter M, Widman G, Surges R, Archibald N, Reid J, Duncan C, Richardson A, Lilleker J, Iorio R, Blaabjerg M, Abeler K, Shin Y. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2017, 141: 348-356. PMID: 29272336, PMCID: PMC5837230, DOI: 10.1093/brain/awx323.Peer-Reviewed Original ResearchMeSH KeywordsADAM ProteinsAdultAgedAged, 80 and overAnalysis of VarianceAntibodiesAnticonvulsantsCognition DisordersDisabled PersonsFemaleFlow CytometryFollow-Up StudiesGreen Fluorescent ProteinsHEK293 CellsHumansImmunotherapyIntracellular Signaling Peptides and ProteinsLimbic EncephalitisMaleMiddle AgedNerve Tissue ProteinsProtein TransportProteinsRetrospective StudiesSeizuresSurveys and QuestionnairesTransfectionYoung AdultConceptsFaciobrachial dystonic seizuresDystonic seizuresCognitive impairmentAddition of immunotherapySerum sodium levelsNormal brain MRIEarly immunotherapyLGI1 antibodiesLimbic encephalitisEpileptogenic mechanismsConsecutive patientsAntiepileptic drugsNormal patientsBrain MRIPatientsSodium levelsImmunotherapyIgG1 antibodiesSeizuresNormal cognitionImpairmentEarly cessationCessationAntibodiesComplex internalization